Clinical

Dataset Information

0

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors


ABSTRACT: This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.

DISEASE(S): Gastric Cancer,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2348822 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2014-11-12 | GSE63207 | GEO
2022-10-06 | GSE214655 | GEO
2023-06-05 | GSE220917 | GEO
2010-06-24 | E-GEOD-22524 | biostudies-arrayexpress
2010-07-19 | GSE21338 | GEO
2010-06-24 | GSE22524 | GEO
2012-10-11 | GSE41478 | GEO
2019-05-04 | GSE130669 | GEO
2010-07-18 | E-GEOD-21338 | biostudies-arrayexpress
2019-05-04 | GSE130658 | GEO